Loading…
Loading…
MSSTF (Mindset Pharma Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
MSSTF does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for MSSTF and 80,000+ other tickers.
See exactly how MSSTF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MSSTF and 80,000+ other tickers.
Mindset Pharma Inc., headquartered in Toronto, Canada, specializes in researching, developing, and commercializing psychedelic therapeutics. These innovative treatments are designed to address neurological and psychiatric conditions for patients in Canada. A primary focus for the company is the ongoing development of MSP-1014, an investigational psychedelic compound.
Toronto, Ontario--(Newsfile Corp. - October 27, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023, September 22, 2023 and October 19, 2023, Otsuka Pharmaceutical Co., Ltd. ("Otsuka"), through its wholly-owned subsidiary Otsuka America, Inc. ("OAI") has acquired all of the issued and outstanding common shares (each, a "Common Share") in the capital of the Company pursuant to an arrangement (the "Arrangement") under Division 5 of Part 9 of the Business Corporations Act (British Columbia) carried out pursuant to an arrangement agreement dated August 31, 2023, between the Company, OAI and 1435816 B.C.
Toronto, Ontario--(Newsfile Corp. - October 25, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023, September 22, 2023, October 5, 2023, and October 19, 2023, the Company has obtained the final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the "Plan of Arrangement") under Division 5 of Part 9 of the Business Corporations Act (British Columbia). Pursuant to the terms of the Plan of Arrangement and an arrangement agreement dated August 31, 2023, between the Company, Otsuka America, Inc. ("OAI") and 1435816 B.C.
Toronto, Ontario--(Newsfile Corp. - October 19, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") is pleased to announce that further to its press releases of August 31, 2023 and September 22, 2023, that the special resolution (the "Special Resolution") in connection with their previously announced statutory plan of arrangement (the "Arrangement") involving, among others, Mindset, Otsuka America, Inc. and 1435816 B.C. Ltd. ("Purchaser") under Division 5 of Part 9 of the Business Corporations Act (British Columbia) whereby, among other things, Purchaser will acquire all of the issued and outstanding common shares of Mindset, was overwhelmingly approved today at the special meeting of shareholders of the Company (the "Meeting").
Toronto, Ontario--(Newsfile Corp. - October 5, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") wishes to clarify certain disclosure in its management information circular (the "Circular") dated September 19, 2023 for its special meeting of the Company's shareholders (the "Shareholders") to approve a statutory plan of arrangement (the "Arrangement") involving, among others, Mindset, Otsuka America, Inc. and 1435816 B.C. Ltd. ("Purchaser") under Division 5 of Part 9 of the Business Corporations Act (British Columbia) whereby, among other things, Purchaser will acquire all of the issued and outstanding common shares of Mindset.
Toronto, Ontario--(Newsfile Corp. - September 22, 2023) - Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) ("Mindset" or the "Company") announces that, further to its press release of August 31, 2023, its management information circular (the "Circular") and related materials were mailed today, September 22, 2023, for its special meeting (the "Meeting") of the Company's shareholders (the "Shareholders") to approve a statutory plan of arrangement (the "Arrangement") involving, among others,Mindset, Otsuka America, Inc. and 1435816 B.C. Ltd. ("Purchaser") under Division 5 of Part 9 of the Business Corporations Act (British Columbia) ("BCBCA") whereby, among other things, Purchaser will acquire all of the issued and outstanding common shares of Mindset.